User: Guest  Login
Title:

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.

Document type:
Journal Article; Research Support, Non-U.S. Gov't; Review
Author(s):
Pradhan, Aruna D; Paynter, Nina P; Everett, Brendan M; Glynn, Robert J; Amarenco, Pierre; Elam, Marshall; Ginsberg, Henry; Hiatt, William R; Ishibashi, Shun; Koenig, Wolfgang; Nordestgaard, Børge G; Fruchart, Jean-Charles; Libby, Peter; Ridker, Paul M
Abstract:
Observational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM-α), pemafibrate, will be used to target residual cardiovascular risk remaining after treatment to reduce low-density lipoprotein cholesterol (LDL-C)...     »
Journal title abbreviation:
Am Heart J
Year:
2018
Journal volume:
206
Pages contribution:
80-93
Fulltext / DOI:
doi:10.1016/j.ahj.2018.09.011
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/30342298
Print-ISSN:
0002-8703
TUM Institution:
Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (Prof. Schunkert)
 BibTeX